Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

NCT01843998 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Cutaneous T-cell Lymphoma (CTCL)

Interventions

DRUG: Sirolimus 0.1% Ointment

Sponsor

Stefan Schieke MD